

David Reddy: Brief Biography

Dr David Reddy has been CEO of Medicines for Malaria Venture since January 2011. Under his leadership, this not-for-profit research foundation has brought forward 6 new antimalarial drugs, broadened its malaria-drug pipeline to include 9 novel drugs in clinical development. MMV's current activities focus on facilitating access to these medications and developing new compounds that address key unmet medical needs such as drug resistance, new medicines for pregnant women and children and simple, easy-to-take and safe drugs to support malaria elimination and eradication.

Prior to joining MMV, David was a Vice President in the Global Product Strategy unit at F. Hoffman-La Roche Ltd, Basel Switzerland, where he served as Pandemic Taskforce Leader. Prior to that he was the Global Franchise Leader for HIV/AIDS at Roche, where he oversaw the successful development and introduction of enfuvirtide, the first HIV fusion inhibitor. He was also responsible for developing Roche's HIV drug access policies and initiatives. His résumé includes over 20 years of 'Pharma' experience, including successful leadership of drug development teams, licensing and alliance management, product and disease area management, market analytics and business planning. His roles also included interfacing with governments, NGOs and patient advocacy groups around access to medicines for priority diseases.

David holds a PhD in Cellular and Molecular Biology from the University of Auckland, New Zealand. His PhD thesis involved cloning the serotypic antigen for rotavirus and development of a recombinant rotavirus vaccine. He completed a post-doctoral fellowship at the Freidrich Miescher Institute in Basel, where he cloned and expressed developmentally-regulated brain-derived microtubule associated proteins.